Personally I would not want to be a buy up here as were hitting major resistance and a choppy trading zone. The monthly chart looks exhausted and ready to take a break. We all know biotechs are crazy, they can run & run and run then on the flip of a dime they crash much harder & faster than they came up.
After having this non-stop run over the past 3 year, I would not be surprised to see a pull-back in the near future even though they had a great 10Q & have plenty of cash from the Janssen deal. Here are some important notes from the 10Q
sec.gov/Archives/edgar/data/879407/000156459019044376/arwr-10k_20190930.htm
We expect that the market price of our Common Stock will continue to fluctuate significantly. We may not continue to generate substantial revenue from the license or sale of our technology for several years, if at all.
We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.
We have incurred net losses since our inception and we expect that our operating losses will continue for the foreseeable future as we continue our drug development and discovery efforts.
Janssen, and the premium JJDC paid on the Company’s common stock during the period.
With this being said I am looking at 6/19/20 $50 Puts
& for more near-term i'm looking at 3/20/20 $50 puts
GLTA
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
